Manufactured by Incyte Corporation, Jakafi is a new FDA-approved drug for the treatment of polycythemia vera (PV) and high-risk myelofibrosis (MF) – rare but serious blood condition that is characterized by abundant red blood cells which thicken the blood and puts patients at risks of blood clots and strokes, and often leads to enlarged spleen.
Although about 50 out of every 100,000 patients suffer from PV in the United States, it often affects older men of 50+ than women, and a quarter of all sufferers experience drug resistance to or intolerance for hydroxyurea. Due to its clonal nature, PV is always categorized as premalignant or malignant by medical doctors and it can always be dangerous – the only joy with this blood condition is that it can be diagnosed with a simple blood test that analysis hemoglobin levels.
Jakafi will be used for the treatment of PV and MF, as well as post-polycythemia vera MF and post-essential thrombocythemia MF. These are all blood conditions that cause thickness of the blood which can lead to blood clots and strokes, as well as painful larger spleen as well as other related problems. Jakafi turns out to be the only available medication for consistent hematocrit control, spleen volume management, and hematological remission for all patients suffering from this rare but manageable blood disorder.